× Medicines Discovery Catapult

Meet Michael Eyres – Post Doc Biomarkers

Which team do you work in and what does that team do? I work with the Biomarkers team, sat within Discovery – we look for markers of disease or treatment, treatment resistance and any other factor associated with drug discovery and clinical targets. What’s your role within your team? I initially started in January as […]

Read more

Working in partnership to tackle antimicrobial resistance in cystic fibrosis

To mark World Antimicrobial Awareness Week, we want to highlight the work we’re doing with the Cystic Fibrosis Trust to address antimicrobial resistance (AMR) in cystic fibrosis (CF) through the CF Syndicate in AMR. The CF Syndicate in AMR drives focused, collaborative efforts to accelerate the discovery and translation to the clinic of new treatments […]

Read more

Meet Emily Offer – Lead Scientist (Biomarkers)

Which team do you work in and what does that team do? I work in the Biomarkers team, within Discovery at MDC. We utilise multiple different technologies that we apply to the broad remit of projects. Typically, the project work depends on the customers and collaborators we are working with. There are a number of […]

Read more

The challenges of accessing clinical samples

Medicines Discovery Catapult launched their sample access capability following a report that was published called ‘State of the Discovery Nation’. The report was based on a survey of UK SMEs around the various challenges in R&D which revealed that whilst access to clinical samples was important, in practice it was challenging to achieve. Importance of […]

Read more

Biomarker identification

Why is biomarker identification so important? Clinical trials are expensive with each phase becoming more expensive as the number of subjects increases, and the attrition rate is high due to a lack of clinical efficacy. Data from the AZ pipeline have shown that programmes that have a Pharmacodynamic (PD) biomarker associated with them, where target […]

Read more

Designing a biomarker strategy

What is a biomarker strategy and why is it important? Within the drug discovery pipeline there are several steps a compound must progress through prior to the clinical stage – initial target identification and validation, lead identification and optimisation and pre-clinical stage. Even so, drugs that enter the clinic still have a high attrition rate […]

Read more

Challenges and Opportunities of Complex Cell Models for Toxicity Testing

Availability of safety data is critical in early studies and in later pre-clinical development. A key focus is to improve the safety related attrition in clinical studies which could be achieved using model systems closer to humans and therefore able to generate more reliable, translatable data. These data can then be used to reliably identify […]

Read more

How to get your molecule into humans

Understanding the main reasons for delay and maximising the opportunities available to improve the efficiency of the transition to first-in-man clinical trials are paramount to the success of a drug development programme. The ultimate aim for a non-clinical program is to ensure the safety of the clinical trial subjects but, to improve the efficiency of […]

Read more

Making safety part of drug design

The importance of safety in the drug discovery process The aims of safety in the drug discovery process are to develop an effective new medicine which can be given to patients quickly and safely. Studies have shown that clinical development attrition rates are high. A study analysing over 7,000 development programs with nearly 10,000 clinical […]

Read more